Capricor Therapeutics price target raised to $43 from $15 at Oppenheimer

Oppenheimer raised the firm’s price target on Capricor Therapeutics to $43 from $15 and keeps an Outperform rating on the shares. The firm has revised its model following the highly favorable regulatory update, by which deramiocel is on a de-risked path to second half of 2025 FDA approval for Duchenne muscular dystrophy-associated cardiomyopathy. Oppenheimer anticipates strong demand for this first therapy capable of addressing what is a leading cause of death in those with DMD.